🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder

Psychopharmacology(2021)10.1007/s00213-021-06008-1Source: DataRank Database

An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder is a research paper published in Psychopharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)OA: greenTopics (22)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Roberta Perciballi,Molly Magill ORCID,Antonella Loche,Roberto Cacciaglia,Lorenzo Leggio ORCID

Live enrichment

PubMed:34731268 PMC:PMC8865311

National Institute on Alcohol Abuse and Alcoholism

Grant: K01 AA023867

National Institute on Alcohol Abuse and Alcoholism

Grant: R01 AA026589

National Institute on Alcohol Abuse and Alcoholism

Grant: R01 AA027760

National Institute on Alcohol Abuse and Alcoholism

Grant: R21 AA027614

National Institute on Alcohol Abuse and Alcoholism

Grant: T32 AA007459

National Institute of General Medical Sciences, Center of Biomedical Research Excellence

Grant: P20 GM130414

Division of Intramural Research, National Institute of Drug Abuse

Grant: ZIA-DA000635

Division of Intramural Research, National Institute on Alcohol Abuse and Alcoholism

Grant: ZIA AA000218

Intramural NIH HHS

Grant: ZIA DA000635

National Institutes of Health

Grant: 5R21AA027614-02

Probenecid as pharmacotherapy for alcohol use disorder

National Institutes of Health

Grant: 5R01AA026589-02

Lead optimization of novel CRFBP-CRFR2 complex modulators for alcohol use disorder

National Institutes of Health

Grant: 1ZIAAA000218-04

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)

National Institutes of Health

Grant: 1ZIADA000635-04

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)

National Institutes of Health

Grant: 5T32AA007459-32

Alcohol Intervention Treatment Outcome Research Training

National Institutes of Health

Grant: 1P20GM130414-01

Center for Addiction and Disease Risk Exacerbation

National Institutes of Health

Grant: 1R01AA027760-01

A focus on alpha-1 blockade as a novel pharmacological treatment for alcohol use disorder

National Institutes of Health

Grant: 5K01AA023867-03

Mifepristone As A Pharmacological Intervention For Stress-Induced Alcohol Drinking

CT Laboratories

greenLicense: Springer Nature TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8865311

publisherhttps://link.springer.com/content/pdf/10.1007/s00213-021-06008-1.pdf

publisherhttps://link.springer.com/article/10.1007/s00213-021-06008-1/fulltext.html

https://doi.org/10.1007/s00213-021-06008-1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865311

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansAlcoholismDouble-Blind MethodAlcohol DrinkingInpatientsLaboratoriesCraving

Keywords

PharmacokineticsPharmacodynamicsMetabotropic Glutamate Receptor Subtype 5 (Mglur5)Alcohol Use Disorder (Aud)Alcohol Dependence (Ad)Get 73AlcoholismInpatientsAlcohol DrinkingDouble-Blind MethodHumansLaboratoriesCraving

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (6)

Effects of blocking mGluR5 on primate dorsolateral prefrontal cortical neuronal firing and working memory performance

Psychopharmacology(2020)

co-citedsame journal

10.1007/s00213-020-05661-2

Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG

Frontiers in Neuroscience(2021)

co-cited

10.3389/fnins.2021.700822

Effects of AFQ056 on language learning in fragile X syndrome

N/A

0.546DataRank · unranked

Journal of Clinical Investigation(2023)

co-cited

10.1172/jci171723

Stepwise activation of a metabotropic glutamate receptor

N/A

1.1DataRank · unranked

Nature(2024)

co-cited

10.1038/s41586-024-07327-x

An Exploratory, Randomized, Double‐Blind Clinical Trial of Dipraglurant for Blepharospasm

Movement Disorders(2024)

co-cited

10.1002/mds.29734

A “double-edged” role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugs

bioRxiv (Cold Spring Harbor Laboratory)(2024)

co-cited

10.1101/2024.01.02.573945